Lakefront Approves Second €50 Million Share Buyback Program
Key Facts
Lakefront Biotherapeutics approved a second €50 million share buyback program, saying in a statement dated November 11 that implementation would begin soon and completion was expected by the end of the first quarter of 2027. The announcement ties the buyback to the company’s year-end liquidity outlook: Chief Financial Officer Aaron Cox said cash and financial investments would total at least €2 billion at the end of 2026. That guidance includes the second program, as well as the earlier program, which has already been completed. The company announced its first program in June, with a value of up to €50 million, and completed it in October. The available information does not specify the number of shares targeted under the new program or its pace of execution.
The company said the first program was completed on October 16, 2026, after it bought back 1.99 million shares at an average price of €25.19 per share. It had announced the program on June 9, with a value of up to €50 million. At its launch, the company said the buyback opportunity was linked to the Gilead transaction, which allowed it to purchase up to $150 million in shares, subject to the availability of distributable reserves. The company described the program’s aim as delivering value to shareholders, while holding the shares it bought as treasury shares. The second program follows completion of that first authorization, while the company has not announced details of the number of shares or the purchase mechanism for the new program.
For the first nine months of 2026, Lakefront reported net revenue of €26.1 million, compared with €211.4 million in the same period of 2025, an 88% year-over-year decline. The company attributed part of the difference to €172.6 million in revenue in the first nine months of 2025, related to recognition of exclusive access rights granted to Gilead for its drug discovery platform. It said deferred income associated with those rights had been fully released as revenue by the end of 2025. In contrast, the company reported net profit of €13.9 million for the first nine months of 2026, after a net loss of €461.3 million in the same period a year earlier. The results place the buyback program amid a sharp decline in reported revenue, as the bottom line returned to profit.
Financial investments, cash and cash equivalents totaled €2,183.1 million on September 30, 2026. The company expects year-end cash and financial investments to range from €2.0 billion to €2.05 billion, including the second €50 million program in that guidance. Cox also said the year-end 2026 outlook was for at least €2 billion and included both the previous and new programs, with the second expected to be completed by the end of the first quarter of 2027. In August, the company had forecast a range of €1.975 billion to €2.050 billion, including the first €50 million program. The comparison shows that the latest guidance also accounts for the second program, while the previously announced upper end remained within the new expected range.
The buyback is part of the company’s capital allocation following the Gilead transaction. In August, it said it expected to retain at least €1.6 billion in cash after funding its pipeline through the first approval of gamgertamig, for strategic deals and other capital allocation priorities. In October, Lakefront completed the sale of its early-stage cell therapy portfolio to Armed Cell Therapeutics for €8 million upfront, with potential milestone payments of up to $230 million. On development, the company expects gamgertamig to enter registrational studies in 2027 and to expand its clinical trial program that year. It also plans to begin proof-of-concept studies in additional immune indications in the first half of 2027. Data on the drug are scheduled to be presented at the American Society of Hematology meeting in New Orleans from December 12 to 15, with an investor webcast on December 14 at 8:00 a.m. Eastern Time.
In the stock market, EL7 data showed LKFT shares closed at $33.98 on November 13, 2026. The close came after the company announced on November 11 that its board had approved the second program, which it said would begin soon. The available information does not include the stock’s session high and low on November 13. The company’s statement also does not specify how many shares may be covered by the new authorization or the dates of individual purchases during the targeted completion period. The announced deadline for completing the program remains the end of the first quarter of 2027.